An interventional study of Cysteine in Classical Homocystinuria, sponsored by Hamad Medical Corporation. Status unknown at 1 site in Qatar. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-02.
Sponsored by Hamad Medical Corporation · Not applicable, Interventional, and Treatment
Classical homocystinuria (HCU) is an autosomal recessive disorder caused by the deficiency of an enzyme cystathionine β-synthase (CβS) that affects the catabolic pathway of the amino acid methionine (Met) which leads to an accumulation of high levels of methionine and Homocysteine causing complications in the multi system. Therefore, a strict dietary management is crucial to maintain good biochemical control, growth parameters and avoid complications. The main objective would be to analyze the impact of the Met restricted diet on growth parameters, biochemical markers and long-term complications in patients up to 18 years. In addition, the efficacy of dietary management with additional cysteine (Cys) supplementation for the patients up to 18 years would also be examined.
The participants of the study would be recruited from the metabolic and genetics clinic in Hamad General Hospital (HGH), Qatar. All Qatari participants with confirmed diagnosis of HCU \<18 years of age will be included in the study. A mixed method study design would be used which include a cross sectional study design to assess the impact of methionine restricted diet on outcome variables and a single arm interventional study to analyze the effect of additional cysteine supplementation in patients from birth to 18 years. For the retrospective study, all the required data would be retrieved from electronic record from the Cerner of HMC and would be stored in a local drive with password protection. Further, all the eligible participants would be prospectively followed to supplement additional cysteine for the period of 6 months.
The collected data will be statistically analyzed using the "SPSS windows version 22.0 software. The study would improve better understanding of dietary management through the identified outcomes. The outcome of Cys supplementation will improve the protein tolerance, biochemical parameters, growth parameters and may standardize the Cys supplementation.
This single-arm interventional study aims to evaluate the efficacy of dietary management combined with additional cysteine (Cys) supplementation in patients with Classical Homocystinuria (HCU). The study will assess the impact on biochemical markers and growth parameters over a six-month period. The study will include pediatric patients from birth to 18 years old, residing in Qatar, a region with the highest global prevalence of HCU.
Classical HCU is an autosomal recessive disorder resulting from a deficiency in cystathionine β-synthase (CβS). This enzymatic deficiency disrupts the metabolism of methionine (Met) and leads to elevated levels of homocysteine (Hcy), while cysteine (Cys) levels remain low. Untreated, HCU can cause significant complications including ectopic lentis, elongated bones, intellectual disability, and thromboembolism. Management primarily involves dietary restrictions to reduce Met intake and supplementation of Cys, along with other treatments.
More research is needed to determine the appropriate cysteine levels in treated patients and whether additional L-cystine supplementation can improve outcomes in those with Classical homocystinuria.
In CBS deficiency, the formation of cysteine from methionine is disrupted, making cysteine a \"conditionally essential\" amino acid. Low cysteine concentrations may contribute to the disease\'s pathogenesis.
The Relationship Between Cysteine and Homocysteine (Hcy) is both cysteine and homocysteine (Hcy) contain thiol groups, and they exist in different reduced and oxidized forms. When Hcy levels are very high, they reduce the concentration of plasma cysteine, likely due to the limited thiol-binding capacity of plasma proteins. Improving homocysteine control by increasing cysteine levels highlights the importance of focusing on cysteine supplementation. Case reports even suggest that cysteine deficiency may lead to poor weight gain and growth, even with adequate energy intake.
Cysteine is added to most methionine-free L-amino acid supplements, but the quantities may not always be sufficient. Administering cysteine can be challenging due to its poor solubility and unpleasant taste.
This provides insight into the complexities of managing CBS deficiency and the potential need for individualized cysteine supplementation.
Despite the known benefits of dietary management, there is limited research on the impact of additional Cysteine supplementation. This study seeks to explore this aspect more comprehensively, especially considering varying practices and guidelines globally.
21 studies on the registry are indexed under Homocystinuria; 5 are open to participants now.
This study's planned enrollment of 50 is above the median of 28 across 13 interventional studies indexed under Homocystinuria.
Browse Homocystinuria studies →Hamad Medical Corporation is the lead sponsor of 137 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All the patients with a confirmed diagnosis of HCU by molecular and biochemical testing who are either diagnosed through NBS or LD who are following the diet
Exclusion Criteria:
✔ Patients with Pyridoxine responsive- homocystinuria
Dietary Supplement: Cysteine
Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.
Also known as: single arm interventional study
improvement of the biochemical parameters specifically homocysteine and methionine levels
Biochemical Parameters: Description: The primary outcome will assess the improvement in biochemical parameters, specifically homocysteine (umol/l) and methionine levels(umol/l), in patients with Homocystinuria (HCU) following Cysteine(Cys) supplementation. Measurement Tool: Blood tests will be used to measure the levels of homocysteine and methionine.
Time frame: Six months
Improvement of growth parameters including weight, Height and BMI
Growth Parameters: Description: The secondary outcome will evaluate changes in growth parameters, including weight, height, and Body Mass Index (BMI), to understand the impact of Cys supplementation on physical growth. Weight Measurement: Measurement Tool: Standard clinical scales. Unit of Measure: Kilograms (kg) Height Measurement: Measurement Tool: Stadiometer or measuring tape. Unit of Measure: Centimeters (cm) BMI Calculation: Calculation: BMI will be calculated using the formula: weight (kg) / height (m²).Unit of Measure: Kilograms per square meter (kg/m²)
Time frame: six month
Plan to share: No — The country has strict laws preventing sharing of IPD to any third party.
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cysteine